Ondansetron-induced muscular contractures in malignant hyperthermia- susceptible individuals

Anesthesia and Analgesia

Volumn 115, Issue 4, 2012, Pages 925-928

  Johannsen, Stephan ^a   Roewer, Norbert ^a   Schuster, Frank ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ONDANSETRON;

ADULT; ARTICLE; CANCER SUSCEPTIBILITY; CLINICAL ARTICLE; CONCENTRATION (PARAMETERS); DRUG SAFETY; FEMALE; HUMAN; HUMAN TISSUE; IN VITRO STUDY; MALE; MALIGNANT HYPERTHERMIA; MUSCLE; MUSCLE CONTRACTURE; MUSCLE TONE; MUSCLE TWITCH; PRIORITY JOURNAL; SKELETAL MUSCLE;

ADULT; DISEASE SUSCEPTIBILITY; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MALE; MALIGNANT HYPERTHERMIA; MIDDLE AGED; MUSCLE CONTRACTION; MUSCLE, SKELETAL; ONDANSETRON; ORGAN CULTURE TECHNIQUES; SEROTONIN 5-HT3 RECEPTOR ANTAGONISTS;

EID: 84866900781     PISSN: 00032999     EISSN: None     Source Type: Journal    
DOI: 10.1213/ANE.0b013e31825d3749     Document Type: Article

References (21)

1. Kranke P, Schuster F, Eberhart LH. Recent advances, trends and economic considerations in the risk assessment, prevention and treatment of postoperative nausea and vomiting. Expert Opin Pharmacother 2007;18:3217-35
2. Gener B, Burns JM, Griffin S, Boyer EW. Administration of ondansetron is associated with lethal outcome. Pediatrics 2010; 125:1514-7
3. Schuster F, Muller-Reible CR. Malignant hyperthermia-diagnostics, treatment and anaesthetic management. Anasthesiol Intensivmed Notfallmed Schmerzther 2009;44:758-63
4. Hopkins PM. Malignant hyperthermia: Pharmacology of triggering. Br J Anaesth 2011;107:48-56
5. The European Malignant Hyperpyrexia Group. A protocol for the investigation of malignant hyperpyrexia (MH) susceptibility. Br J Anaesth 1984;56:1267-9
6. Larach MG, for the North American Malignant Hyperthermia Group. Standardization of the caffeine halothane muscle contracture test. Anesth Analg 1989;69:511-5
7. Gener B, Muldoon S, Burns JM, Va'zques M, Garcia-Bragado F, Boyer EW, Rosenberg H. Fatal awake and related to anesthesia malignant hyperthermia RyR-1 linked episodes in twins. 30th Annual Meeting of the European Malignant Hyperthermia Group. Nijmegen 2011:27-8
8. Groom L, Muldoon SM, Tang ZZ, Brandom BW, Bayarsaikhan M, Bina S, Lee HS, Qiu X, Sambuughin N, Dirksen RT. Identical de novo mutation in the type 1 ryanodine receptor gene associated with fatal, stress-induced malignant hyperthermia in two unrelated families. Anesthesiology 2011;115:938-45
9. Sambuughin N, Sei Y, Gallagher KL, Wyre HW, Madsen D, Nelson TE, Fletcher JE, Rosenberg H, Muldoon SM. North American malignant hyperthermia population: Screening of the ryanodine receptor gene and identification of novel mutations. Anesthesiology 2001;95:594-9
10. Rueffert H, Wehner M, Ogunlade V, Meinecke C, Schober R. Mild clinical and histopathological features in patients who carry the frequent and causative malignant hyperthermia RyR1 mutation p.Thr2206Met. Clin Neuropathol 2009;28:409-16
11. Kim JH, Jarvik GP, Browning BL, Halsall J, Hopkins PM. Exome sequencing and identity by descent (IBD) analysis in malignant hyperthermia gene discovery. Anesthesiology 2011; A:1572
12. Wappler F, Roewer N, Kochling A, Scholz J, Loscher W, Steinfath M. Effects of the serotonin2 receptor agonist DOI on skeletal muscle specimens from malignant hyperthermiasusceptible patients. Anesthesiology 1996;84:1280-7
13. Loscher W, Witte U, Fredow G, Ganter M, Bickhardt K. Pharmacodynamic effects of serotonin (5-HT) receptor ligands in pigs: Stimulation of 5-HT2 receptors induces malignant hyperthermia. Naunyn Schmiedebergs Arch Pharmacol 1990;341: 483-93
14. Ooms L, Awouters F, Degryse A, Jageneau T. Serotonin and S2 antagonists in veterinary medicine. In: Ruckebusch Y, Toutain PL, Koritz GD, eds. Veterinary Pharmacology and Toxicology. 1st ed. Boston: MTP Press, 1983:263-81
15. Wappler F, Scholz J, Oppermann S, von Richthofen V, Steinfath M, Schulte am Esch J. Ritanserin attenuates the in vitro effects of the 5-HT2 receptor agonist DOI on skeletal muscles from malignant hyperthermia-susceptible patients. J Clin Anesth 1997;9:305-11
16. Garber AJ. Inhibition of serotonin of amino acid release and protein degradation in skeletal muscle. Mol Pharmacol 1977;13: 640-51
17. Watcha MF, White PF. Postoperative nausea and vomiting. Its etiology, treatment, and prevention. Anesthesiology 1992;77: 162-84
18. Paul M, Callahan R, Au J, Kindler CH, Yost CS. Antiemetics of the 5-hydroxytryptamine 3A antagonist class inhibit muscle nicotinic acetylcholine receptors. Anesth Analg 2005;101:715-21
19. Figg WD, Graham CL, Hak LJ, Dukes GE. Ondansetron: A novel antiemetic agent. South Med J 1993;86:497-502
20. Wappler F, Anetseder M, Baur CP, Censier K, Doetsch S, Felleiter P, Fiege M, Fricker R, Halsall PJ, Hartung E, Heffron JJ, Heytens L, Hopkins PM, Klingler W, Lehmann-Horn F, Nivoche Y, Tegazzin V, Tzanova I, Urwyler A, Weisshorn R, Schulte am Esch J. Multicentre evaluation of in vitro contracture testing with bolus administration of 4-chloro-m-cresol for diagnosis of malignant hyperthermia susceptibility. Eur J Anaesthesiol 2003;20:528-36
21. Anetseder M, Ritter L, Horbaschek H, Hartung E, Roewer N. The impact of 4-chloro-m-cresol in heparin formulas on malignant hyperthermia: In vitro and in vivo. Acta Anaesthesiol Scand 2000;44:338-42